Press Release: Cures Within Reach Names its 2022 Patient Impact Award Recipients

Cures Within Reach Names its 2022 Patient Impact Award Recipients

David C. Fajgenbaum, MD, MBA, MSc of Penn Medicine / CDRC and Incyte to be honored in 2022

June 2, 2022

Cures Within Reach, a global nonprofit leading the use of medical repurposing research that tests approved therapies in new indications to improve patients’ lives, today announced its 2022 Patient Impact Award recipients:

• David C. Fajgenbaum, MD, MBA, MSc of PennMedicine and the Castleman Disease Collaborative Network is the recipient of the 2022 Janet Davison Rowley Patient Impact Research Award

   

• Incyte is the recipient of the 2022 Patient Impact Industry Award

Cures Within Reach (www.cureswithinreach.org) will recognize David and Incyte for their outstanding achievements in creating impact for patients by identifying and testing existing medicines in newdiseases at a patient education event in 2022.

Cures Within Reach celebrates and honors:

• David Fajgenbaum’s tireless efforts not only to identify a repurposed treatment for his own rare disease, but also to study and advance this therapeutic option and others for other patients as Co-Founder of the Castleman Disease Collaborative Network and his continued efforts to encourage repurposing as well as his recent activities to find, grade and advance therapies for COVID-19.
• Incyte’s efforts in bringing ruxolitinib to patients with several different rare blood cancers and for complications following bone marrow transplant, as well as supporting ongoing clinical trials using these approved therapies for pediatric indications.

“I – and countless other Castleman disease patients – are literally alive today because of treatment soriginally developed for other diseases that we repurposed,” said Dr. Fajgenbaum. “How many more drugs are sitting at our neighborhood pharmacies that could be life-saving treatments for patients without any? I am so thankful for the work Cures Within Reach does to uncover these treatments andhonored to receive this award.” “I am impressed by the interest in ruxolitinib from the scientific community. While our Incyte researchers continue to blaze new trails with their work, so much of what we know today that could benefit patients results directly from exploration of pathways led by researchers outside of or in partnership with our company,” said Barry Flannelly, Pharm.D., Executive Vice President and General Manager, NorthAmerica, Incyte. “This honor recognizes our continued commitment to advancing science and we are grateful to receive the award.”

For more information on these awardees, upcoming events and CWR, visit https://bit.ly/ CWRGHRA22.